君實生物(688180.SH)：控股子公司與吉盛澳瑪簽署許可及合作協議
格隆匯9月26日丨君實生物(688180.SH)公佈，公司控股子公司君拓生物與吉盛澳瑪簽署了許可及合作協議。根據許可及合作協議，吉盛澳瑪授予君拓生物在大中華區基於許可知識產權研發、改進、製造、生產、使用、申報、註冊、商業化和以其他任何方式利用許可產品的獨佔許可權利，並與君拓生物在大中華區外合作開發IAMA-001鼻噴劑型項目。君拓生物將根據項目進展向吉盛澳瑪支付相應首付款、里程碑款及銷售提成。許可及合作協議簽署後，君拓生物將向吉盛澳瑪支付4,000萬元人民幣首付款。君拓生物將根據許可產品研發進展向吉盛澳瑪支付不超過2.4億元人民幣的大中華區研發里程碑，並在許可產品首個適應症獲得美國及歐盟藥品監管部門上市批准後向吉盛澳瑪支付不超過1.5億美元的大中華區外研發里程碑。君拓生物將根據許可產品在大中華區的銷售情況向吉盛澳瑪支付不超過2.5億元人民幣的銷售里程碑，以及許可產品在大中華區年度淨銷售額個位數百分比的銷售提成。
IAMA-001小核酸免疫調節劑鼻用噴霧劑型藥物是吉盛澳瑪自主研發的一款創新型免疫調節小核酸鼻用噴霧劑，主要用於治療季節性過敏性鼻炎，是全球首個自主研發並進入臨牀試驗階段的鼻噴免疫調節小核酸藥物。目前許可產品已完成中國Ⅰ期臨牀試驗，展示了優越的安全性和耐受性，並展示了靶標介導的生物學活性，即將進入Ⅱ期臨牀試驗階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
